GlassScriptPhysician profile
Alpa Sharma
NPI 1508881392
$851.17
in general payments reported to CMS, 2019-2025
17 companies · $670 in 2025
The $670 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $181 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $168.80 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $167.23 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $85.41 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Idorsia Pharmaceuticals US INC | $84.79 | 2024 | Tryvio, Quviviq |
| Amgen INC. | $63.59 | 2024-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $50.48 | 2025 | Ozempic |
| Axsome Therapeutics, INC. | $48.22 | 2025 | Symbravo, Sunosi |
| Teva Pharmaceuticals USA, INC. | $29.84 | 2025 | Ajovy |
| Sumitomo Pharma America, INC. | $21.26 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $19.89 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.71 | 2025 | Xifaxan |
| Ardelyx, INC. | $17.87 | 2025 | Ibsrela |
| Exact Sciences Corporation | $16.00 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.07 | 2025 | Gardasil 9, Capvaxive |
| Xeris Pharmaceuticals, INC. | $14.82 | 2025 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.18 | 2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $14.01 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpa Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.